Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 46

1.

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group.

N Engl J Med. 2017 Sep 28;377(13):1228-1239. doi: 10.1056/NEJMoa1612917. Epub 2017 Sep 14.

PMID:
28910237
2.

Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.

Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P; UNITI–IM-UNITI Study Group.

N Engl J Med. 2016 Nov 17;375(20):1946-1960.

3.

The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.

de Zeeuw D, Bekker P, Henkel E, Hasslacher C, Gouni-Berthold I, Mehling H, Potarca A, Tesar V, Heerspink HJ, Schall TJ; CCX140-B Diabetic Nephropathy Study Group.

Lancet Diabetes Endocrinol. 2015 Sep;3(9):687-96. doi: 10.1016/S2213-8587(15)00261-2. Epub 2015 Aug 9.

PMID:
26268910
4.

The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months.

Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes Care. 2015 May;38(5):940-2. doi: 10.2337/dc14-2787. Epub 2015 Mar 10.

5.

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.

Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM; ODYSSEY COMBO II Investigators.

Eur Heart J. 2015 May 14;36(19):1186-94. doi: 10.1093/eurheartj/ehv028. Epub 2015 Feb 16.

6.

A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history.

Sosenko JM, Skyler JS, DiMeglio LA, Beam CA, Krischer JP, Greenbaum CJ, Boulware D, Rafkin LE, Matheson D, Herold KC, Mahon J, Palmer JP; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2015 Feb;38(2):271-6. doi: 10.2337/dc14-1813. Epub 2014 Dec 17.

7.

The variant allele of the rs188140481 polymorphism confers a moderate increase in the risk of prostate cancer in Polish men.

Antczak A, Wokołorczyk D, Kluźniak W, Kashyap A, Jakubowska A, Gronwald J, Huzarski T, Byrski T, Dębniak T, Masojć B, Górski B, Gromowski T, Gołąb A, Sikorski A, Słojewski M, Gliniewicz B, Borkowski T, Borkowski A, Przybyła J, Sosnowski M, Małkiewicz B, Zdrojowy R, Sikorska-Radek P, Matych J, Wilkosz J, Różański W, Kiś J, Bar K, Janiszewska H, Stawicka M, Milecki P, Lubiński J, Narod SA, Cybulski C; Polish Hereditary Prostate Cancer Consortium.

Eur J Cancer Prev. 2015 Mar;24(2):122-7. doi: 10.1097/CEJ.0000000000000079.

PMID:
25187206
8.

Orphenadrine-induced convulsive status epilepticus in rats responds to the NMDA antagonist dizocilpine.

Rejdak K, Nieoczym D, Czuczwar M, Kiś J, Wlaź P, Turski WA.

Pharmacol Rep. 2014 Jun;66(3):399-403. doi: 10.1016/j.pharep.2013.12.007. Epub 2014 Apr 2.

PMID:
24905515
9.

Partial cystectomy in a 76 year old patient suffering from small cell carcinoma of the urinary bladder.

Starownik R, Korolczuk A, Bar K, Płaza P, Kiś J, Muc K, Bar M.

Cent European J Urol. 2013;66(2):159-62. doi: 10.5173/ceju.2013.02.art12. Epub 2013 Aug 13.

10.

Network analysis of neurotransmitter related human kinase genes: possible role of SRC, RAF1, PTK2B?

Brys Z, Pluhar A, Kis JT, Buda B, Szabo A.

Neuropsychopharmacol Hung. 2013 Sep;15(3):165-71. Review.

11.

A common nonsense mutation of the BLM gene and prostate cancer risk and survival.

Antczak A, Kluźniak W, Wokołorczyk D, Kashyap A, Jakubowska A, Gronwald J, Huzarski T, Byrski T, Dębniak T, Masojć B, Górski B, Gromowski T, Nagorna A, Gołąb A, Sikorski A, Słojewski M, Gliniewicz B, Borkowski T, Borkowski A, Przybyła J, Sosnowski M, Małkiewicz B, Zdrojowy R, Sikorska-Radek P, Matych J, Wilkosz J, Różański W, Kiś J, Bar K, Domagała P, Stawicka M, Milecki P, Akbari MR, Narod SA, Lubiński J, Cybulski C; Polish Hereditary Prostate Cancer Consortium; Other members of the Polish Hereditary Prostate Cancer Consortium, Bryniarski P, Paradysz A, Jersak K, Niemirowicz J, Słupski P, Jarzemski P, Skrzypczyk M, Dobruch J, Domagała W, Chosia M, van de Wetering T, Serrano-Fernández P, Puszyński M, Soczawa M, Switała J, Archimowicz S, Kordowski M, Zyczkowski M, Borówka A, Bagińska J, Krajka K, Szwiec M, Haus O, Janiszewska H, Stembalska A, Sąsiadek MM.

Gene. 2013 Dec 15;532(2):173-6. doi: 10.1016/j.gene.2013.09.079. Epub 2013 Oct 2.

PMID:
24096176
12.

The presence of prostate cancer at biopsy is predicted by a number of genetic variants.

Kashyap A, Kluźniak W, Wokołorczyk D, Gołąb A, Sikorski A, Słojewski M, Gliniewicz B, Świtała J, Borkowski T, Borkowski A, Antczak A, Wojnar Ł, Przybyła J, Sosnowski M, Małkiewicz B, Zdrojowy R, Sikorska-Radek P, Matych J, Wilkosz J, Różański W, Kiś J, Bar K, Bryniarski P, Paradysz A, Jersak K, Niemirowicz J, Słupski P, Jarzemski P, Skrzypczyk M, Dobruch J, Domagała P, Piotrowski K, Jakubowska A, Gronwald J, Huzarski T, Byrski T, Dębniak T, Górski B, Masojć B, van de Wetering T, Menkiszak J, Akbari MR, Lubiński J, Narod SA, Cybulski C; Polish Hereditary Prostate Cancer Consortium.

Int J Cancer. 2014 Mar 1;134(5):1139-46. doi: 10.1002/ijc.28447. Epub 2013 Sep 16.

13.

Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants.

Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes. 2013 Dec;62(12):4179-83. doi: 10.2337/db13-0656. Epub 2013 Jul 17.

14.

The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients.

Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC, Rafkin L, Schatz D, Eisenbarth G; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2013 Sep;36(9):2615-20. doi: 10.2337/dc13-0425. Epub 2013 Jul 1.

15.

A personalised approach to prostate cancer screening based on genotyping of risk founder alleles.

Cybulski C, Wokołorczyk D, Kluźniak W, Kashyap A, Gołąb A, Słojewski M, Sikorski A, Puszyński M, Soczawa M, Borkowski T, Borkowski A, Antczak A, Przybyła J, Sosnowski M, Małkiewicz B, Zdrojowy R, Domagała P, Piotrowski K, Menkiszak J, Krzystolik K, Gronwald J, Jakubowska A, Górski B, Dębniak T, Masojć B, Huzarski T, Muir KR, Lophatananon A, Lubiński J, Narod SA; Polish Hereditary Prostate Cancer Consortium.

Br J Cancer. 2013 Jun 25;108(12):2601-9. doi: 10.1038/bjc.2013.261. Epub 2013 May 30.

16.

The G84E mutation in the HOXB13 gene is associated with an increased risk of prostate cancer in Poland.

Kluźniak W, Wokołorczyk D, Kashyap A, Jakubowska A, Gronwald J, Huzarski T, Byrski T, Dębniak T, Gołąb A, Gliniewicz B, Sikorski A, Switała J, Borkowski T, Borkowski A, Antczak A, Wojnar L, Przybyła J, Sosnowski M, Małkiewicz B, Zdrojowy R, Sikorska-Radek P, Matych J, Wilkosz J, Różański W, Kiś J, Bar K, Bryniarski P, Paradysz A, Jersak K, Niemirowicz J, Słupski P, Jarzemski P, Skrzypczyk M, Dobruch J, Domagała P, Akbari MR, Lubiński J, Narod SA, Cybulski C; Polish Hereditary Prostate Cancer Consortium.

Prostate. 2013 Apr;73(5):542-8. doi: 10.1002/pros.22594. Epub 2013 Jan 17.

PMID:
23334858
17.

An inherited NBN mutation is associated with poor prognosis prostate cancer.

Cybulski C, Wokołorczyk D, Kluźniak W, Jakubowska A, Górski B, Gronwald J, Huzarski T, Kashyap A, Byrski T, Dębniak T, Gołąb A, Gliniewicz B, Sikorski A, Switała J, Borkowski T, Borkowski A, Antczak A, Wojnar L, Przybyła J, Sosnowski M, Małkiewicz B, Zdrojowy R, Sikorska-Radek P, Matych J, Wilkosz J, Różański W, Kiś J, Bar K, Bryniarski P, Paradysz A, Jersak K, Niemirowicz J, Słupski P, Jarzemski P, Skrzypczyk M, Dobruch J, Domagała P, Narod SA, Lubiński J; Polish Hereditary Prostate Cancer Consortium.

Br J Cancer. 2013 Feb 5;108(2):461-8. doi: 10.1038/bjc.2012.486. Epub 2012 Nov 13.

18.

Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies.

Yu L, Boulware DC, Beam CA, Hutton JC, Wenzlau JM, Greenbaum CJ, Bingley PJ, Krischer JP, Sosenko JM, Skyler JS, Eisenbarth GS, Mahon JL; Type 1 Diabetes TrialNet Study Group.

Diabetes Care. 2012 Jun;35(6):1213-8. doi: 10.2337/dc11-2081. Epub 2012 Mar 23.

19.

Kynurenic acid in human renal cell carcinoma: its antiproliferative and antimigrative action on Caki-2 cells.

Walczak K, Zurawska M, Kiś J, Starownik R, Zgrajka W, Bar K, Turski WA, Rzeski W.

Amino Acids. 2012 Oct;43(4):1663-70. Epub 2012 Feb 21.

PMID:
22349835
20.

Nefopam enhances the protective activity of antiepileptics against maximal electroshock-induced convulsions in mice.

Czuczwar M, Czuczwar K, Cięszczyk J, Kiś J, Saran T, Łuszczki JJ, Turski WA.

Pharmacol Rep. 2011;63(3):690-6.

Supplemental Content

Loading ...
Support Center